BACK

Vivian Xu

Vivian Xu

Vice President

New York Office  |  vivian.xu@torreya.com   |   212.257.6026

Vivian Xu, a Vice President at Torreya, provides transaction support for companies across different sectors in the healthcare industry.

Before joining Torreya’s team in 2016, Vivian worked as an Investment Analyst for the healthcare investment team at Fosun Group.

Vivian earned a B.A. in international journalism and communication as well as international economics and trade from Beijing Foreign Studies University. She received her M.A. in public administration from Columbia University, with a concentration in finance and energy. Vivian speaks Mandarin and has extensive experience in English-Chinese two-way translation.

Selected Transactions

HBT Labs
Acquired by
American Regent
August 2022
Common Sensing
Sale of intellectual property to
Bigfoot Biomedical
June 2021
Eikonizo
R&D collaboration agreement with
Otsuka
February 2021
Nuvation Bio
Advisor to the Special Committee of the Board of Directors in its merger with
Panacea
$1.5 billion
October 2020
Durect
License of US rights to Posimir® to
Sandoz
$293 million
May 2017
Sesen Bio
License of Vicineum™ in Greater China Region to
Qilu Pharmaceutical
$12 million upfront
July 2020
Calliditas
License of Nefecon in Greater China and Singapore to
Everest
Up to $121 million
June 2019
EyePoint
License of Durasert™ in Ophthalmology in the Greater China Region to
Ocumension Therapeutics
Up to $11.75 million
November 2018
Sandoz
Sale of
Sevelamer ANDA to
TWI Pharmaceuticals
October 2018
EA Pharma
License of AJT-240 in hemodialysis in China to
Tasly Pharmaceutical Group Co., Ltd.
Up to $24 million
June 2018
Sandoz
Sale of
ANDA portfolio to
CASI Pharmaceuticals
January 2018
Sandoz
Sale of OTC
portfolio to
PLD
December 2017
Sandoz
Sale of
generics portfolio to
FosunPharma
$18 million
August 2017
Essential Pharmaceuticals
Asset sale to
Accord
July 2017